Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 2005, p. 1949-1956, Vol. 49, No. 5
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.5.1949-1956.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin
Jacob Strahilevitz and
David C. Hooper*
Division of Infectious Diseases, Massachusetts General Hospital Harvard Medical School Boston, Massachusetts 02114
Received 26 July 2004/
Returned for modification 26 September 2004/
Accepted 4 January 2005
Quinolones that act equally against DNA gyrase and topoisomerase IV are a desirable modality to decrease the selection of resistant strains. We first determined by genetic and biochemical studies in Staphylococcus aureus that the primary target enzyme of WCK-1734, a new quinolone, was DNA gyrase. A single mutation in gyrase, but not topoisomerase IV, caused a two- to fourfold increase in the MIC. Studies with purified topoisomerase IV and gyrase from S. aureus also showed that gyrase was more sensitive than topoisomerase IV to WCK-1734 (50% inhibitory concentration, 1.25 and 2.5 to 5.0 µg/ml, respectively; 50% stimulation of cleavage complex formation, 0.62 and 2.5 to 5.0 µg/ml, respectively). To test the effect of balanced activity of quinolones against the two target enzymes, we measured the frequency of selection of mutants with ciprofloxacin (which targets topoisomerase IV) and WCK-1734 alone and in combination. With the combination of ciprofloxacin and WCK-1734, each at its MIC, the ratio of frequency of mutants selected was significantly lower than that with each drug alone at two times their respective MICs. We further characterized resistant strains selected with the combination of ciprofloxacin and WCK-1734 and found evidence to suggest the existence of novel mutational mechanisms for low-level quinolone resistance. By use of a combination of differentially targeting quinolones, this study provides novel data in direct support of the paradigm for dual targeting of quinolone action and reduced development of resistance.
* Corresponding author. Mailing address: Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114-2696. Phone: (617) 726-3812. Fax: (617) 726-7416. E-mail:
dhooper{at}partners.org.
Antimicrobial Agents and Chemotherapy, May 2005, p. 1949-1956, Vol. 49, No. 5
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.5.1949-1956.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Cambau, E., Matrat, S., Pan, X.-S., Roth Dit Bettoni, R., Corbel, C., Aubry, A., Lascols, C., Driot, J.-Y., Fisher, L. M.
(2009). Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother
63: 443-450
[Abstract]
[Full Text]
-
German, N., Malik, M., Rosen, J. D., Drlica, K., Kerns, R. J.
(2008). Use of Gyrase Resistance Mutants To Guide Selection of 8-Methoxy-Quinazoline-2,4-Diones. Antimicrob. Agents Chemother.
52: 3915-3921
[Abstract]
[Full Text]
-
Okumura, R., Hirata, T., Onodera, Y., Hoshino, K., Otani, T., Yamamoto, T.
(2008). Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother
62: 98-104
[Abstract]
[Full Text]
-
Grossman, T. H., Bartels, D. J., Mullin, S., Gross, C. H., Parsons, J. D., Liao, Y., Grillot, A.-L., Stamos, D., Olson, E. R., Charifson, P. S., Mani, N.
(2007). Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds. Antimicrob. Agents Chemother.
51: 657-666
[Abstract]
[Full Text]
-
Bhagwat, S. S., Mundkur, L. A., Gupte, S. V., Patel, M. V., Khorakiwala, H. F.
(2006). The Anti-Methicillin-Resistant Staphylococcus aureus Quinolone WCK 771 Has Potent Activity against Sequentially Selected Mutants, Has a Narrow Mutant Selection Window against Quinolone-Resistant Staphylococcus aureus, and Preferentially Targets DNA Gyrase . Antimicrob. Agents Chemother.
50: 3568-3579
[Abstract]
[Full Text]
-
Strahilevitz, J., Robicsek, A., Hooper, D. C.
(2006). Role of the Extended {alpha}4 Domain of Staphylococcus aureus Gyrase A Protein in Determining Low Sensitivity to Quinolones. Antimicrob. Agents Chemother.
50: 600-606
[Abstract]
[Full Text]
-
Hurdle, J. G., O'Neill, A. J., Chopra, I.
(2005). Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents. Antimicrob. Agents Chemother.
49: 4821-4833
[Full Text]
-
Strahilevitz, J., Truong-Bolduc, Q. C., Hooper, D. C.
(2005). DX-619, a Novel Des-Fluoro(6) Quinolone Manifesting Low Frequency of Selection of Resistant Staphylococcus aureus Mutants: Quinolone Resistance beyond Modification of Type II Topoisomerases. Antimicrob. Agents Chemother.
49: 5051-5057
[Abstract]
[Full Text]